Company news

Matricelf Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program

September 3, 2026

Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones

July 9, 2026

Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

June 22, 2026

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

June 17, 2026

Matricelf Advances Toward First in Human Trial with Initiation of GMP Manufacturing Program

June 9, 2026

Matricelf Enters Strategic Collaboration with Japan's CiRA Foundation to Advance Next-Generation Regenerative Manufacturing

March 30, 2026

Matricelf (TASE: MTLF) Enters Strategic Collaboration with Sheba Medical Center to Advance First in Human Clinical Program in Spinal Cord Injury

March 24, 2026

Matricelf Ltd. (TASE: MTLF) Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile of Its Personalized Spinal Cord Implant

March 4, 2026

Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy

March 3, 2026

Matricelf Named Most Innovative Company of 2026 at Advanced Therapies Week in San Diego

March 2, 2026

Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board

February 27, 2026

Matricelf to Attend The Digital Spine & Pain Neuroscience Summit 2026 in Phoenix, Arizona

February 26, 2026

Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation

February 26, 2026

Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments

March 11, 2025

Decks